- Home
- SPRO vs GEG Comparison
SPRO vs GEG Comparison
Compare SPRO & GEG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPRO
- GEG
- Stock Information
- Founded
- SPRO 2013
- GEG 1994
- Country
- SPRO United States
- GEG United States
- Employees
- SPRO N/A
- GEG N/A
- Industry
- SPRO Biotechnology: Pharmaceutical Preparations
- GEG Computer Software: Prepackaged Software
- Sector
- SPRO Health Care
- GEG Technology
- Exchange
- SPRO Nasdaq
- GEG Nasdaq
- Market Cap
- SPRO 63.0M
- GEG 55.6M
- IPO Year
- SPRO 2017
- GEG N/A
- Fundamental
- Price
- SPRO $0.97
- GEG $1.79
- Analyst Decision
- SPRO Buy
- GEG
- Analyst Count
- SPRO 4
- GEG 0
- Target Price
- SPRO $5.00
- GEG N/A
- AVG Volume (30 Days)
- SPRO 247.7K
- GEG 22.9K
- Earning Date
- SPRO 11-14-2024
- GEG 02-11-2025
- Dividend Yield
- SPRO N/A
- GEG N/A
- EPS Growth
- SPRO N/A
- GEG N/A
- EPS
- SPRO 0.06
- GEG N/A
- Revenue
- SPRO $106,455,000.00
- GEG $18,516,000.00
- Revenue This Year
- SPRO N/A
- GEG N/A
- Revenue Next Year
- SPRO N/A
- GEG N/A
- P/E Ratio
- SPRO $15.29
- GEG N/A
- Revenue Growth
- SPRO 37.01
- GEG 83.09
- 52 Week Low
- SPRO $0.92
- GEG $1.70
- 52 Week High
- SPRO $1.89
- GEG $2.12
- Technical
- Relative Strength Index (RSI)
- SPRO 39.40
- GEG 45.94
- Support Level
- SPRO $0.92
- GEG $1.76
- Resistance Level
- SPRO $1.13
- GEG $1.82
- Average True Range (ATR)
- SPRO 0.06
- GEG 0.03
- MACD
- SPRO 0.00
- GEG -0.00
- Stochastic Oscillator
- SPRO 26.16
- GEG 23.08
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
About GEG Great Elm Group Inc.
Great Elm Group Inc operates as an alternative asset manager focused on growing a scalable and diversified portfolio of long-duration and permanent capital vehicles across credit, real estate, specialty finance, and other alternative strategies. Along with its subsidiaries, it manages Great Elm Capital Corp, a publicly traded business development company, and Monomoy Properties REIT, LLC, an industrial-focused real estate investment trust, in addition to other investments.